These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
124 related items for PubMed ID: 38127110
21. Immunosuppressive agents for treating IgA nephropathy. Vecchio M, Bonerba B, Palmer SC, Craig JC, Ruospo M, Samuels JA, Molony DA, Schena FP, Strippoli GF. Cochrane Database Syst Rev; 2015 Aug 03; (8):CD003965. PubMed ID: 26235292 [Abstract] [Full Text] [Related]
22. Kidney transplantation outcomes in patients with IgA nephropathy and other glomerular and non-glomerular primary diseases in the new era of immunosuppression. Lionaki S, Makropoulos I, Panagiotellis K, Vlachopanos G, Gavalas I, Marinaki S, Liapis G, Michelakis I, Bokos I, Boletis I. PLoS One; 2021 Aug 03; 16(8):e0253337. PubMed ID: 34403416 [Abstract] [Full Text] [Related]
24. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents. Whitson BA, Kilic A, Lehman A, Wehr A, Hasan A, Haas G, Hayes D, Sai-Sudhakar CB, Higgins RS. Clin Transplant; 2015 Jan 24; 29(1):9-17. PubMed ID: 25284138 [Abstract] [Full Text] [Related]
25. Impact of Induction Immunosuppression on the Recurrence of Primary IgA Nephropathy. Lee KW, Kim KS, Lee JS, Yoo H, Kim K, Park JB, Kwon GY, Kim SJ. Transplant Proc; 2019 Jun 24; 51(5):1491-1495. PubMed ID: 31010698 [Abstract] [Full Text] [Related]
26. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. 3C Study Collaborative Group, Haynes R, Harden P, Judge P, Blackwell L, Emberson J, Landray MJ, Baigent C, Friend PJ. Lancet; 2014 Nov 08; 384(9955):1684-90. PubMed ID: 25078310 [Abstract] [Full Text] [Related]
27. Primary pediatric deceased-donor kidney transplant recipients outcomes by immunosuppression induction received in the United States. Riad S, Jackson S, Chinnakotla S, Verghese P. Pediatr Transplant; 2021 Aug 08; 25(5):e13928. PubMed ID: 33314638 [Abstract] [Full Text] [Related]
28. Depleting Antibody Induction and Kidney Transplant Outcomes: A Paired Kidney Analysis. Sampaio MS, Chopra B, Sureshkumar KK. Transplantation; 2017 Oct 08; 101(10):2527-2535. PubMed ID: 28475563 [Abstract] [Full Text] [Related]
29. The long-term outcome of renal transplantation of IgA nephropathy and the impact of recurrence on graft survival. Moroni G, Longhi S, Quaglini S, Gallelli B, Banfi G, Montagnino G, Messa P. Nephrol Dial Transplant; 2013 May 08; 28(5):1305-14. PubMed ID: 23229925 [Abstract] [Full Text] [Related]
30. Risk for graft loss in pediatric and young adult kidney transplant recipients due to recurrent IgA nephropathy. Engen RM, Bartosh SM, Smith JM, Perkins JD, Harshman LA. Am J Transplant; 2024 Jan 08; 24(1):37-45. PubMed ID: 37595842 [Abstract] [Full Text] [Related]
31. Outcomes following Kidney transplantation in IgA nephropathy: a UNOS/OPTN analysis. Kadiyala A, Mathew AT, Sachdeva M, Sison CP, Shah HH, Fishbane S, Jhaveri KD. Clin Transplant; 2015 Oct 08; 29(10):911-9. PubMed ID: 26190417 [Abstract] [Full Text] [Related]
32. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy. Hussain SM, Marcus RJ, Ko TY, Nashar K, Thai NL, Sureshkumar KK. Exp Clin Transplant; 2016 Jun 08; 14(3):287-93. PubMed ID: 27221720 [Abstract] [Full Text] [Related]
33. Evaluation of tonsillectomy before kidney transplantation in patients with IgA nephropathy. Sato Y, Ishida H, Shimizu T, Tanabe K. Transpl Immunol; 2014 Jan 08; 30(1):12-7. PubMed ID: 24246415 [Abstract] [Full Text] [Related]
34. Predicting Post-Transplant Recurrence of IgA Nephropathy: The Importance of Crescents. Avasare RS, Rosenstiel PE, Zaky ZS, Tsapepas DS, Appel GB, Markowitz GS, Bomback AS, Canetta PA. Am J Nephrol; 2017 Jan 08; 45(2):99-106. PubMed ID: 28056461 [Abstract] [Full Text] [Related]
35. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. Lü TM, Yang SL, Wu WZ, Tan JM. Chin Med J (Engl); 2011 Mar 08; 124(5):664-8. PubMed ID: 21518554 [Abstract] [Full Text] [Related]
36. Effect of induction agent on posttransplant outcomes in deceased donor kidney transplant recipients: influence of race. Hussain SM, Sureshkumar KK, Ko TY, Marcus RJ. Transplant Proc; 2013 Mar 08; 45(1):119-21. PubMed ID: 23283292 [Abstract] [Full Text] [Related]
37. Influence of steroid maintenance on the outcomes in deceased donor kidney transplant recipients experiencing delayed graft function. Tangirala B, Marcus RJ, Hussain SM, Sureshkumar KK. Indian J Nephrol; 2013 Nov 08; 23(6):403-8. PubMed ID: 24339515 [Abstract] [Full Text] [Related]
38. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Ciancio G, Burke GW, Gaynor JJ, Roth D, Kupin W, Rosen A, Cordovilla T, Tueros L, Herrada E, Miller J. Clin Transplant; 2008 Nov 08; 22(2):200-10. PubMed ID: 18339140 [Abstract] [Full Text] [Related]
39. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC. Transpl Immunol; 2008 Nov 08; 20(1-2):32-42. PubMed ID: 18773960 [Abstract] [Full Text] [Related]
40. The clinical outcomes of second kidney transplantation in IgA nephropathy: a multicenter retrospective study. Baek CH, Lee JG, Park JH, Kim H, Yang WS, Kim YS, Huh WS, Yang J, Han DJ, Park SK. Clin Nephrol; 2016 Aug 08; 86(2):87-93. PubMed ID: 27345187 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]